| 白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析 |
| 投稿时间：2017-06-15 修订日期：2017-10-23 点此下载全文 |
| 引用本文：聂力,葛卫红.白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析[J].药学实践杂志,2017,35(6):562~564,568 |
| 摘要点击次数: 1052 |
| 全文下载次数: 893 |
|
|
| 中文摘要:目的 分析白三烯受体拮抗剂在哮喘患者中的抗炎、改善免疫功能的效果。方法 选取鼓楼医院2014年8月至12月收治的86例哮喘患者为研究对象，随机分为对照组（43例）和观察组（43例），对照组采用常规治疗+沙美特罗替卡松粉吸入剂（舒利迭50 μg/250 μg），观察组在对照组的基础上采用白三烯受体拮抗剂（孟鲁司特钠片），两组疗程均为14 d。比较两组炎性因子、免疫功能的变化，以评估治疗方案的有效性，同时比较两组的不良反应。结果 观察组的炎性因子如IL-6、TNF-α及CRP较之对照组均有所降低，差异有统计学意义（P<0.05）。观察组的免疫功能指标如CD4+、CD4+/CD8+高于对照组，CD8+均低于对照组，差异有统计学意义（P<0.05）。观察组经治疗后的ACT评分较之对照组有所提高，且总有效率也高于对照组，差异有统计学意义（P<0.05）。两组患者在治疗过程中均未出现明显不良反应。结论 白三烯拮抗剂（孟鲁司特）在哮喘治疗中能够发挥抗炎和改善免疫功能的效果，这可能是其提高哮喘治疗效果的重要机制。 |
| 中文关键词:白三烯受体拮抗剂 哮喘 抗炎 免疫功能 |
| |
| Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients |
|
|
| Abstract:Objective To analyze the effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients.Methods 86 cases of asthma patients in our hospital from August to December 2014 were taken as the research objects, they were randomly divided into the observation group with 43 cases and the control group with 43 cases, the control group was treated with conventional therapy plus Seretide, the observation group was given leukotriene receptor antagonist-montelukast based on the control group, two groups were treated for 14 d. The changes of inflammatory factors and immune function, therapeutic effect, adverse reaction were compared between the two groups after treatment. In the observation group after the treatment,the IL-6, TNF-α and CRP were lower than that in the control group, the difference was statistically significant (P<0.05). In the observation group after the treatment, CD4+ and CD4+/CD8+ were higher than that in the control group, CD8+ was lower than that in the control group, the difference was statistically significant (P<0.05). After the treatment in the observation group, the ACT score was higher than that in the control group, the total effective rate was higher than that in the control group, the difference was statistically significant (P<0.05). There was no obvious adverse reaction in the two groups. Conclusion Leukotriene antagonist (montelukast) could play an important role in improving the immune function and anti-inflammation in asthma patients, which might be an important mechanism to improve the therapeutic effect of asthma. |
| keywords:leukotriene receptor antagonist asthma anti-inflammatory immune function |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
